Doxorubicin

Common Uses

Doxorubicin is used to treat many different types of cancer in both adults and children. It works by slowing or stopping the growth of cancer cells. It is often used as part of a combination treatment plan with other chemotherapy medications.

Cancers of the Blood and Lymph System

• Leukemia: Including acute lymphoblastic leukemia and acute myeloblastic leukemia.
• Lymphoma: Including Hodgkin disease and non-Hodgkin lymphoma.
• Multiple Myeloma: Often used in its liposomal form in combination with other drugs.

Solid Tumors and Other Cancers

This medication is frequently prescribed for various solid tumors, including:

• Breast cancer
• Ovarian cancer
• Bladder cancer
• Thyroid cancer
• Stomach cancer
• Lung cancer

Pediatric and Specialized Uses

Doxorubicin is also used to treat specific conditions such as:

• Sarcomas: Cancers of the bone and soft tissues.
• Wilms tumor: A type of kidney cancer in children.
• Neuroblastoma: A cancer that develops from immature nerve cells.
• Kaposi sarcoma: Specifically AIDS-related Kaposi sarcoma, typically treated with the liposomal formulation.

Mechanism of Action

Doxorubicin belongs to a class of drugs known as anthracyclines. It is designed to target cells that are dividing rapidly, which is a primary characteristic of cancer cells. The medication works in several ways to disrupt the life cycle of these cells:

• DNA Interference: The drug binds directly to the DNA inside cells. This prevents the cell from being able to read or copy its genetic instructions, which is necessary for the cell to function and divide.
• Enzyme Blocking: Doxorubicin inhibits an enzyme called topoisomerase II. This enzyme is responsible for repairing and uncoiling DNA during cell division. By blocking this enzyme, the drug causes permanent damage to the DNA strands, eventually leading to cell death.
• Free Radical Damage: The medication also promotes the production of free radicals. These are highly reactive molecules that can damage the membranes and other internal components of cancer cells.

Because cancer cells typically divide much faster than healthy cells, they are more susceptible to the effects of doxorubicin. However, because the drug travels through the entire body, it can also affect some healthy cells that divide quickly, such as those in the hair follicles or the lining of the digestive tract.

Common Side Effects

• Nausea and vomiting
• Temporary hair loss
• Mouth sores or pain in the throat
• Loss of appetite or diarrhea
• Red-colored urine, which is a harmless effect of the medication's color and may last for 1 to 2 days after a dose
• Changes in skin or nail appearance, such as darkening
• General weakness or fatigue

Serious Side Effects

Contact your healthcare provider immediately if you experience any of the following:

• Signs of heart problems, including shortness of breath, swelling in the feet or ankles, and a rapid or irregular heartbeat
• Signs of infection, such as fever, chills, or a sore throat that does not go away
• Unusual bruising or bleeding, or small red spots on the skin
• Pain, burning, redness, or swelling at the site where the drug was injected
• Severe skin reactions, such as redness, pain, or peeling on the palms of the hands or soles of the feet
• Extreme tiredness, dizziness, or pale skin
• Symptoms that may indicate a secondary cancer, such as new or unusual fatigue or bone pain

Serious Heart Risks

Doxorubicin can cause severe and permanent damage to the heart muscle, which may lead to congestive heart failure. This risk is cumulative, meaning it increases with the total amount of the drug received over a lifetime. Heart function is typically monitored before, during, and after treatment using specialized imaging tests to measure how well the heart pumps blood.

Bone Marrow Suppression

This medication can cause a significant drop in white blood cells, red blood cells, and platelets. This condition, known as myelosuppression, can lead to:

• Increased risk of life-threatening infections.
• Anemia and extreme fatigue.
• Easy bruising or serious bleeding.

Secondary Malignancies

Patients treated with doxorubicin have an increased risk of developing secondary cancers later in life, particularly acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). This risk may be higher when doxorubicin is used in combination with certain other chemotherapy drugs or radiation therapy.

Tissue Damage at Injection Site

Doxorubicin is a vesicant, meaning it can cause severe tissue damage, blistering, and necrosis (cell death) if it leaks out of the vein during administration. If a patient experiences pain, burning, or redness at the injection site, the infusion must be stopped immediately to prevent deep tissue injury.

Liver Function

The liver is responsible for clearing doxorubicin from the body. Patients with impaired liver function are at a higher risk for toxicity, and healthcare providers may need to adjust the dosage based on the results of liver function tests.

Pregnancy and Reproductive Health

Doxorubicin can cause fetal harm if administered during pregnancy. Effective birth control is recommended for both men and women during treatment and for a specific period afterward. The medication may also lead to permanent loss of fertility in both men and women. Breastfeeding is generally not recommended during treatment due to the potential for serious adverse reactions in the infant.

Pregnancy

Doxorubicin is known to cause fetal harm when administered during pregnancy. It may lead to birth defects or pregnancy loss. Healthcare providers typically recommend a pregnancy test before starting treatment to ensure the patient is not pregnant.

Patients of reproductive potential are advised to use effective contraception to prevent pregnancy:

• Females: Use effective birth control during treatment and for at least 6 months after the final dose.
• Males: Use effective contraception during treatment and for at least 3 months after the final dose if the partner is capable of becoming pregnant.

If pregnancy occurs during treatment, the patient should contact their healthcare provider immediately to discuss the potential risks to the fetus.

Breastfeeding

Doxorubicin and its breakdown products pass into breast milk. Because of the potential for severe adverse reactions in a nursing child, breastfeeding is not recommended during treatment. Current guidelines suggest waiting at least 6 days after the final dose of doxorubicin before resuming breastfeeding.

Available Forms

Doxorubicin is administered as an injection or infusion into a vein by a healthcare provider. It is available in the following forms:

• Injectable Solution: A liquid formulation that is diluted before administration.
• Powder for Injection: A freeze-dried (lyophilized) powder that must be reconstituted with a sterile liquid before use.
• Liposome Injection: A specialized formulation where the medication is encapsulated in liposomes (tiny fat-like particles). This form has different properties and is not interchangeable with standard doxorubicin hydrochloride formulations.

FDA Approval and Indications

Doxorubicin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several types of cancer. These include various leukemias, lymphomas, and solid tumors such as breast, ovary, bladder, and lung cancers, as well as certain types of sarcomas.

Boxed Warnings

The FDA has issued several boxed warnings for doxorubicin, which are the most serious type of warning for a medication. These warnings include:

• Cardiotoxicity: The drug can cause severe heart damage or heart failure, which may occur during treatment or years after therapy has ended. The risk increases with the total cumulative dose received.
• Myelosuppression: Doxorubicin can cause a severe decrease in blood cell counts, which may lead to serious infections, anemia, or bleeding problems.
• Secondary Malignancies: There is a risk of developing secondary cancers, such as acute myelogenous leukemia (AML), after treatment.
• Extravasation: If the drug leaks into the surrounding tissue during intravenous administration, it can cause severe local tissue necrosis and scarring.
• Hepatic Impairment: Patients with impaired liver function may require lower doses to avoid increased toxicity.

Regulatory Oversight

Doxorubicin is a prescription-only medication that must be administered under the supervision of a physician experienced in the use of cancer chemotherapy. Because of its high toxicity and the specialized monitoring required, it is typically administered by healthcare professionals in a hospital or clinical setting.

FDA-Approved Indications

Doxorubicin is approved by the FDA for the treatment of several types of cancer, often as part of a multi-drug chemotherapy regimen. These include:

• Breast cancer
• Ovarian cancer
• Bladder cancer
• Thyroid cancer
• Gastric (stomach) cancer
• Hodgkin's and non-Hodgkin's lymphoma
• Acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML)
• Wilms' tumor and neuroblastoma
• Soft tissue and bone sarcomas

The liposomal formulation of doxorubicin has specific FDA approvals for treating AIDS-related Kaposi's sarcoma, multiple myeloma (in combination with bortezomib), and advanced ovarian cancer.

FDA Boxed Warnings

The FDA requires doxorubicin to carry boxed warnings, which are the most serious warnings for prescription drugs. These warnings highlight the following risks:

• Cardiotoxicity: Doxorubicin can cause severe and potentially fatal heart damage or congestive heart failure. This risk is cumulative, meaning it increases with the total amount of the drug received over a lifetime.
• Secondary Malignancies: Patients treated with doxorubicin have an increased risk of developing secondary cancers, particularly acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).
• Bone Marrow Suppression: The drug can cause a severe decrease in blood cells produced by the bone marrow, leading to serious infections, anemia, or excessive bleeding.
• Extravasation Risk: If the drug leaks out of the vein into the surrounding tissue during administration, it can cause severe local tissue necrosis (death) and skin damage.
• Hepatic Impairment: Because the drug is processed by the liver, patients with liver disease are at a higher risk of toxicity and may require dose adjustments.